Last reviewed · How we verify
Apixaban 2.5 mg
Apixaban 2.5 mg, marketed by Janssen Research & Development, LLC, is a well-established anticoagulant with a strong presence in the pharmaceutical market. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the eventual entry of generic competitors post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Apixaban 2.5 mg |
|---|---|
| Also known as | Eliquis, Eliquis 2,5mg, ELIQUIS |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD (NA)
- Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS (NA)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (PHASE3)
- Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis (PHASE1)
- Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD) (PHASE4)
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apixaban 2.5 mg CI brief — competitive landscape report
- Apixaban 2.5 mg updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI